On The Pen GLP-1 News

Dave Knapp GLP-1 Industry Insider

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

About PodLP

PodLP is the leading podcast app for feature phones. With 10M+ installs in nearly every country, PodLP is available for KaiOS on the KaiStore and JioStore, as well as Cloud Phone. If you're interested in promoting "On The Pen GLP-1 News" on PodLP, contact sales@podlp.com.

Screenshots are mockup renders of PodLP for KaiOS. Actual design may vary based on platform, operating system, and app version.

On The Pen GLP-1 News

Episodes (175)

Feb 24th NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?
Feb 17th Wegovy vs Zepbound in 2026: New Higher Dose
Feb 10th Compound Tirzepatide: Time to Stock Up?

On The Pen GLP-1 News

Feb 24, 2026
27½ minutes
19 MB

Send a text This episode unpacks Novo’s aggressive price cuts, Lilly’s head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war. 00:00 – Cold Open: Lilly vs Novo Shock Timing Dave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match. 03:20 – Novo Nordisk Price Cuts Explained Deep dive into Novo’s plan to cut list prices by up to 50...

On The Pen GLP-1 News

NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?

Dave Knapp GLP-1 Industry Insider

00:00 -27:26